Journal of Clinical Oncology
Articles in this Issue
Daratumumab in the frontline management of newly diagnosed multiple myeloma: An overview of systematic reviews and meta-analyses.
248 Background: We conducted an overview of systematic reviews and meta-analyses (SRMAs) to evaluate daratumumab’s effect...
Pivotal PYNNACLE phase 2 trial of rezatapopt in heavily pre-treated, advanced solid tumors with a <i>TP53</i> Y220C mutation: Initial ovarian cancer analysis.
201 Background: TP53 Y220C mutations occur in ~3% of ovarian cancers. Rezatapopt, an investi...
Multimodal spatiotemporal atlas to reveal CCDC3 <sup>+</sup> CAFs as drivers of liver metastasis in colorectal cancer.
25 Background: Colorectal cancer liver metastasis (CRLM) exhibits pronounced heterogeneity and dynamic evolution of the im...
National cancer control plans in Southeast Asia: A systematic comparison.
327 Background: Southeast Asia (SEA) is experiencing a significant increase in cancer burden with 1.15 million new cases r...
Efficacy of perioperative esketamine on postoperative recovery in patients with breast cancer undergoing modified radical mastectomy: A systematic review and meta-analysis.
54 Background: Modified radical mastectomy (MRM) causes significant acute postoperative and potential chronic pain. Esketa...
AI-driven oncogenic risk stratification in pediatric autism spectrum disorder: A multi-omic machine learning framework for early cancer prevention.
12 Background: Children with Autism Spectrum Disorder (ASD), particularly those with co-occurring intellectual disabilitie...
Dose modifications, toxicity, and survival with enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): Real-world experience in Alberta, Canada.
188 Background: EVP has demonstrated a survival benefit in advanced urothelial carcinoma (aUC) clinical trials. However re...
Real-world performance of a multimodal cell-free DNA multi-cancer early detection test in Asian populations.
14 Background: Multi-cancer early detection (MCED) addresses a critical unmet need by enabling simultaneous screening for...
Effect of VAV1 on metastasis and immune evasion in squamous cell carcinoma.
228 Background: Cancer progression is shaped by continuous adaptation to environmental constraints. While metastatic disse...
Perioperative analgesic approaches in hepatobiliary cancer malignancies: Experience from a tertiary care centre.
156 Background: Peri-operative analgesic management in hepatobiliary cancer surgeries is crucial for enhancing patient rec...
Efficacy of exercise-based interventions for the management of chemotherapy-induced peripheral neuropathy in patients with breast cancer: A systematic review and meta-analysis.
53 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting side effect in breast cance...
Glycosylation signature to predict response to immune checkpoint blockade in lung cancer.
272 Background: Immune checkpoint blockade (ICB) has improved long-term survival in non-small cell lung cancer (NSCLC); ho...
Identification of novel CD8+ immune epitopes relevant for EBV-related cancers.
88 Background: EBV infects 95% of the world’s population and is associated with EBV related cancers that include Asian pre...
Cross-continental transportability of phase III trial results to LMIC cohort with locally advanced NSCLC: A g-computation analysis with layered decomposition.
276 Background: Clinical trial results are frequently extrapolated to populations that were never part of Western RCTs, su...
CanAssist Breast in routine clinical care: A real-world single-centre experience.
49 Background: In Asian HR+/HER2- early-stage breast cancer (EBC) patients, data on prognostication using Western prognost...
Revolutionizing AML MRD: Gene-level kinetics to uncover chemoresistant clones and predict relapse risk via NGS.
252 Background: Minimal residual disease (MRD) assessment in AML remains binary in practice, despite heterogeneity across...
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus statins and the risk of hepatocellular carcinoma (HCC) and hepatic decompensation in patients with type 2 diabetes mellitus (T2DM).
139 Background: Statins have been shown to reduce the risk of HCC in high-risk populations with metabolic diseases. Howeve...
Efficacy and safety of immune checkpoint inhibitors in recurrent platinum-resistant ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.
212 Background: Recurrent platinum-resistant ovarian cancer (PROC) is associated with poor prognosis and limited therapeut...
Real-world efficacy of cabozantinib in combination with pemetrexed and carboplatin followed by pemetrexed-cabozantinib maintenance as first-line therapy for metastatic KRAS-mutant lung adenocarcinoma.
278 Background: KRAS-mutant advanced non-small-cell lung cancers (NSCLC) have shown suboptimal outcomes on standard chemo-...
Bridging critical disparities: A telementoring approach to equitable palliative care in Malaysia.
334 Background: Recent evidence shows substantial urban-rural disparities in palliative care access across Malaysia, with...
Patient preference for large language model (LLM)–optimised oncology trial information: A randomised controlled crossover study.
6 Background: Clinical trial participation in oncology is frequently hindered by complex, jargon-laden information that im...
Analytical validation of a 90-gene expression assay for pan-cancer tissue-of-origin classification in Southeast Asia.
16 Background: Accurate identification of the tissue of origin (TOO) is critical for enabling site-specific therapy in pat...
Mechanistically guided therapeutic strategy for BAP1 mutant tumors through protein stability and chromatin modulation.
307 Background: Mutations in BAP1 occur across multiple cancers and are associated with aggressive clinical phenotypes and...
Targeted delivery of topotecan via folic acid functionalized phycocyanin nanoparticles for ovarian cancer.
86 Background: Ovarian cancer remains the deadliest gynecologic malignancy due to late-stage diagnosis and frequent treatm...
Real-world comparative effectiveness and safety of sotorasib versus adagrasib in previously treated KRAS G12C-mutant non-small cell lung cancer: A propensity score-matched cohort study.
282 Background: Sotorasib and adagrasib are selective KRAS G12C inhibitors approved for previously treated advanced NSCLC....